top of page
galaxy_bg_no_stars.png
Songenova_logo-icon_light.png

Songenova

Membraneless perfusion. Intelligent automation. Boundless scale-up.

With AI accelerating drug discovery, new cell and gene therapies are being developed faster than we can manufacture them. Songenova is building bioreactors to close that gap before it becomes the same bottleneck that stalled antibody manufacturing.

TECHNOLOGY
 

The CentriFLEX Bioreactor

CENTRIFUGAL FLUIDIZED EXPANSION

2021-06-10_CentriFLEX_edited_edited_edit

Our technology retains cells by balancing centrifugal forces with opposing medium flow. 

No membrane filters.

 

No fouling.

​​​​
Performance highlights:

  • Reach 100 million cells/mL in under 7 days.

  • Grow cells at 95% of the maximum specific growth rate.

  • Maintain expected cell phenotypes and functionality.

  • Limit operator-interaction and prevent excess use of valuable culture medium with process-informed feeding controls. 

  • Save space with the 0.25 cubic meter footprint.

  • Easily transition between runs with single-use tubing kits and system-integrated HEPA filters and UV-C sterilization switches.

TEAM
 

We believe no incredible feat is accomplished alone. Every individual draws inspiration, motivation, and wisdom from the people around them.

2026_Kaiphanliam_1x1_edited.jpg

Kitana Kaiphanliam, PhD

Co-Founder & CEO

IMG_134401_0_edited.jpg

Eric Barrow

Co-Founder & VP of Prototype Development

Bernard Van Wie_edited.jpg

Bernard Van Wie, PhD

Engineering Advisor

William Davis_edited_edited_edited.jpg

William Davis, PhD

Microbiology Advisor

PUBLICATION HIGHLIGHTS
 

Human T lymphoblastic leukemia cell line expansion (NEW! 2026-06-15)

Fraser-Hevlin B, Kaiphanliam KM, Moore Z, Davis WC, and Van Wie BJ (2026). A centrifugal bioreactor for immunotherapy: modeling and optimization of the growth of human T lymphoblastic leukemia cells. Biotechnology and Bioprocess Engineering. https://doi.org/10.1007/s12257-026-00298-y

Bovine CD8 cytotoxic T cell line expansion

Kaiphanliam KM, Fraser-Hevlin B, Barrow ES, Davis WC,  and Van Wie BJ (2023). Development of a centrifugal bioreactor for rapid expansion of CD8 cytotoxic T cells for use in cancer immunotherapy. Biotechnology Progress, 39(6):e3388. https://aiche.onlinelibrary.wiley.com/doi/10.1002/btpr.3388

Digital twin development with cybersecurity applications

Fraser-Hevlin B, Schuler AW, Gozen AB, and Van Wie BJ (2024). Using digital twins to protect biomanufacturing from cyberattacks, Military Cyber Affairs, 7(1), Article 7. https://digitalcommons.usf.edu/mca/vol7/iss1/7/

LSWI logo.png

WIN Mentoring Program

LSINW Pitch Demo

(audience choice award)

Life Science Washington

image.png

National I-Corps led by Interior Northeast Hub

at Cornell University (award no. 2403974)

 

Early Grant for Exploratory Research

(EAGER award no. 1645249)

National Science Foundation

TRACTION
 

image.png

Founders' Forum

Women in Bio

San Diego

UW logo.png

University of Washington

PRESS
 

Co-authors with CentriFLEX 1.jpg

New technology developed at WSU will help doctors grow cancer-fighting white blood cells

image.png

CONTACT US
 

bottom of page